
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is well-positioned in the growing field of AI-driven medical diagnostics and wound healing. With its cutting-edge DeepView System and recent FDA clearance, the company is poised for strong revenue growth in the coming years. Additionally, its recent funding from BARDA and plans for a miniaturized handheld version of DeepView demonstrate a commitment to innovation and expansion in the market. These factors, combined with the large and under-penetrated market opportunity for advanced wound care, lead to a positive outlook for Spectral AI's stock.
Bears say
Spectral AI is expected to recognize revenue in line with its FY26 guidance of $18.5M from its existing BARDA contract, but its limited operating history and potential competition in the AI medical diagnostic market could pose risks to its commercial success. While FDA clearance for its DeepView system is a significant milestone, risks to its rating and PT include delays to regulatory and clinical timelines and limited reimbursement. A discounted sales analysis forecasts revenue of $18.5M at 5.5x NTM EV/Sales, leading to a $4 PT.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares